An AI-powered biomarker based on histology alone predicted survival among men with metastatic hormone-sensitive prostate cancer and identified those who benefitted from escalation to triplet therapy.
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a medicine that is used to treat prostate cancer in adults. Pluvicto may be used to treat PSMA-positive prostate cancer that has spread to other ...
For better cancer care in India, Novartis India has announced the launch of Pluvicto (lutetium (177Lu) vipivotide tetraxetan), the country’s first regulatory authority approved radioligand therapy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results